Burning Rock Biotech (NASDAQ:BNR) Trading 0.1% Higher – Here’s What Happened

by · The Cerbat Gem

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report)’s share price rose 0.1% during trading on Thursday . The stock traded as high as $18.42 and last traded at $17.05. Approximately 35,702 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 64,003 shares. The stock had previously closed at $17.03.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BNR. Wall Street Zen downgraded Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

View Our Latest Research Report on BNR

Burning Rock Biotech Price Performance

The company has a market capitalization of $169.49 million, a PE ratio of -9.49 and a beta of 1.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.91 and a current ratio of 3.14. The stock has a 50 day moving average price of $13.66 and a two-hundred day moving average price of $8.77.

Institutional Trading of Burning Rock Biotech

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Burning Rock Biotech in the 3rd quarter valued at $26,000. Prospera Financial Services Inc acquired a new position in Burning Rock Biotech during the third quarter worth $214,000. Finally, Crcm LP raised its holdings in Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after buying an additional 26,809 shares in the last quarter. 30.03% of the stock is owned by institutional investors.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Read More